DelveInsight’s, “Metastatic Triple-Negative Breast Cancer Pipeline Insight 2023” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Metastatic Triple-Negative Breast Cancer (mTNBC) pipeline landscape. It covers the Metastatic Triple-Negative Breast Cancer pipeline drug profiles, including Metastatic Triple-Negative Breast Cancer clinical trials and nonclinical stage products. It also covers the Metastatic Triple-Negative Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To explore more information on the latest breakthroughs in the Metastatic Triple-Negative Breast Cancer Pipeline treatment landscape of the report, click here @ Metastatic Triple-Negative Breast Cancer Pipeline Outlook

 

Metastatic Triple-Negative Breast Cancer Overview

Breast cancer (BC) is the most common malignant neoplasm in females. Approximately 10–20% of BCs do not express estrogen and progesterone receptors and lack amplification/overexpression of the human epidermal growth factor 2 receptor (HER2); therefore, they are known as triple-negative breast cancers (TNBCs) and constitute an aggressive histologic subtype. Overall prognosis for patients with mTNBC is worse than for the other BC subtypes, and more effective therapeutic options are needed.

 

Key Takeaways from the Triple-Negative Breast Cancer Pipeline Report

• DelveInsight’s Metastatic Triple-Negative Breast Cancer Pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Metastatic Triple-Negative Breast Cancer.
• The leading Metastatic Triple-Negative Breast Cancer Companies include G1 Therapeutics, CytoDyn, Merck, Gilead Sciences, AstraZeneca, Hoffmann-La Roche, Celegene, and Others
• Promising Metastatic Triple-Negative Breast Cancer Pipeline Therapies include pembrolizumab, capecitabine, eribulin, Sacituzumab Govitecan-hziy, Paclitaxel, Atezolizumab, Ipatasertib, B013+Nab-Paclitaxel, Gemcitabine, and others
• The Metastatic Triple-Negative Breast Cancer companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Triple-Negative Breast Cancer R&D. The Metastatic Triple-Negative Breast Cancer therapies under development are focused on novel approaches to treat/improve Metastatic Triple-Negative Breast Cancer.

 

For further information, refer to the detailed Metastatic Triple-Negative Breast Cancer Unmet Needs, Metastatic Triple-Negative Breast Cancer Market Drivers, and Metastatic Triple-Negative Breast Cancer Market Barriers, click here for Metastatic Triple-Negative Breast Cancer Ongoing Clinical Trial Analysis

 

Metastatic Triple-Negative Breast Cancer Emerging Drugs Profile

 

• Trilaciclib: G1 Therapeutics

Trilaciclib is a first-in-class FDA-designated “Breakthrough Therapy” designed to improve outcomes for people with cancer who are treated with chemotherapy. In June 2019, the company announced preliminary overall survival (OS) data from a randomized Phase 2 trial, which demonstrated that women with Metastatic Triple-Negative Breast Cancer (mTNBC) lived significantly longer when receiving trilaciclib and chemotherapy compared with women receiving chemotherapy alone.

 

• Leronlimab (PRO 140): CytoDyn

Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. CytoDyn is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer.

 

Request a sample and discover the recent advances in Metastatic Triple-Negative Breast Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Metastatic Triple-Negative Breast Cancer Treatment Landscape

 

Metastatic Triple-Negative Breast Cancer Pipeline Therapeutics Assessment

There are approx. 4+ Metastatic Triple-Negative Breast Cancer companies which are developing the Metastatic Triple-Negative Breast Cancer therapies. The Metastatic Triple-Negative Breast Cancer companies which have their Metastatic Triple-Negative Breast Cancer (mTNBC) drug candidates in the most advanced stage, i.e. phase II include, G1 Therapeutics.

 

Dive deep into rich insights for drugs for Metastatic Triple-Negative Breast Cancer Pipeline, click here @ Metastatic Triple-Negative Breast Cancer Unmet Needs and Analyst Views

 

Scope of the Metastatic Triple-Negative Breast Cancer Pipeline Report

• Coverage- Global
• Brain Metastasis from Breast Cancer Companies- Angiochem Inc, Novartis, Merck Sharp & Dohme Corp., AstraZeneca, Criterium Inc, Bristol-Myers Squibb, Bayer, Northwest Biotherapeutics, Array BioPharma, and others
• Brain Metastasis from Breast Cancer Pipeline Therapies- Efaproxiral, NKTR-102, Eribulin, Ixabepilone, capecitabine, lapatinib, trastuzumab, and others.
• Brain Metastasis from Breast Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Metastatic Triple-Negative Breast Cancer Mergers and acquisitions, Metastatic Triple-Negative Breast Cancer Licensing Activities @ Metastatic Triple-Negative Breast Cancer Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Executive Summary
3. Metastatic Triple-Negative Breast Cancer (mTNBC): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic Triple-Negative Breast Cancer (mTNBC)– DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Metastatic Triple-Negative Breast Cancer (mTNBC) Collaboration Deals
9. Mid Stage Products (Phase II)
10. Trilaciclib: G1 Therapeutics
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. Drug name: Company name
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Metastatic Triple-Negative Breast Cancer (mTNBC) Key Companies
17. Metastatic Triple-Negative Breast Cancer (mTNBC) Key Products
18. Metastatic Triple-Negative Breast Cancer (mTNBC)- Unmet Needs
19. Metastatic Triple-Negative Breast Cancer (mTNBC)- Market Drivers and Barriers
20. Metastatic Triple-Negative Breast Cancer (mTNBC)- Future Perspectives and Conclusion
21. Metastatic Triple-Negative Breast Cancer (mTNBC) Analyst Views
22. Metastatic Triple-Negative Breast Cancer (mTNBC) Key Companies
23. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services